Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials

Baseline severity of atopic dermatitis (AD) may influence treatment response. The objective of this analysis was to assess short- and long-term abrocitinib efficacy and safety by baseline AD severity. A post-hoc analysis of patients (aged ≥ 12 years) with moderate-to-severe AD receiving abrocitinib 100 mg or 200 mg or placebo in two studies—JADE COMPARE (ClinicalTrials.gov ID: NCT03720470) and JAD…